Therapy is the first to extend lifespan in advanced cases.
A drug that takes an unusual approach to harnessing patients' immune systems to fight cancer has been approved by the US Food and Drug Administration (FDA). On 25 March, the FDA cleared ipilimumab, produced by Bristol-Myers Squibb, based in New York, to treat advanced melanoma, a particularly lethal form of skin cancer. Although the drug typically lengthens a patient's life by only 4 months or so, in clinical trials a fraction of patients lived much longer.
Ipilimumab marks success on two fronts: advanced melanoma, which has beaten multiple drug candidates, and cancer immunotherapy, which has had several high-profile disappointments in late-stage clinical trials.
Unlike other cancer immunotherapies on the market, which stimulate the immune system, ipilimumab lifts one of the immune system's restraints. The drug is an antibody that targets the protein cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 guards against autoimmune reactions by inhibiting some T cells, but can also keep the immune system from attacking cancers. "The other therapies slam on the immune system's gas pedal," says Patrick Hwu, an oncologist at the MD Anderson Cancer Center in Houston, Texas. "Ipilimumab releases the brakes."
Hwu helped to conduct some of the first clinical trials of the drug more than five years ago. Although patients with advanced melanoma rarely survive more than a year past their diagnosis, some of those initial participants are still alive, he says, years after receiving their final dose of ipilimumab. This stands in stark contrast to the widely hailed genetically targeted melanoma drugs, called BRAF inhibitors, that are currently wending their way through clinical trials. The inhibitors produce dramatic responses in patients whose melanoma has mutations in the BRAF protein, but the cancer becomes resistant about seven months after starting the drug (see Nature 467, 140–141; 2010).
Although ipilimumab can add years of life, only 20–30% of patients show any benefit at all (F. S. Hodi et al. N. Engl. J. Med. 363, 711–723; 2010). "We clearly have to do much better than that," says Hwu. Furthermore, the drug caused severe or fatal side effects in almost 13% of patients, prompting the FDA to qualify its approval with a mitigation strategy.
Ultimately, the key may be to combine ipilimumab with targeted therapies such as the BRAF inhibitors, says James Allison, an immunologist at the Memorial Sloan-Kettering Cancer Center in New York. The targeted therapy would rapidly kill the cancer cells in more patients than would benefit from ipilimumab alone. That wave of destruction might then scatter cellular debris that could catch the attention of an immune system boosted by ipilimumab, yielding a more durable response. "To me this is the area with the most excitement," Allison says.
Related links in Nature Research
Nature Reviews Drug Discovery: Ipilimumab trial watch
Related external links
Rights and permissions
About this article
Cite this article
Ledford, H. Melanoma drug wins US approval. Nature 471, 561 (2011). https://doi.org/10.1038/471561a
This article is cited by
The oncogenic role of tubulin alpha-1c chain in human tumours
BMC Cancer (2022)
rs2013278 in the multiple immunological-trait susceptibility locus CD28 regulates the production of non-functional splicing isoforms
Human Genomics (2022)
The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients
Scientific Reports (2022)
Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity
British Journal of Cancer (2022)
Next generation of immune checkpoint inhibitors and beyond
Journal of Hematology & Oncology (2021)